GENE ONLINE|News &
Opinion
Blog

The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq

by GeneOnline
Share To
AbbVie has published its financial report recently, showing that its top-selling drug Humira, known as adalimumab, has made great sales again at USD 20.7 billion. Humira has been the best-selling monoclonal antibody drug of AbbVie since marketing, however, is going to lose the protection from patent regulation in 2023. Pharmaceutical companies with biosimilar molecule drugs are expected to join the fierce competition, including Amgen, Samsung, Boehringer Ingelheim, Mylan, Novartis, and Pfizer.

GO Prime with only $1.49 now

LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!